Stroma Biosciences

WHAT’S NEW

Stroma accepted as a Milner Therapeutics Institute Frameshift company

by | Mar 5, 2022 | No category, Press releases

We have been accepted as a Milner Therapeutics Institute Frameshift company providing us with access to state-of-the art of office and lab space in the Cambridge Biomedical Campus

(more information found: https://www.milner.cam.ac.uk/ and https://www.milner.cam.ac.uk/frame-shift/ )

LATEST NEWS

Stroma Biosciences Announces Appointment of New Chairman

Stroma Biosciences Announces Appointment of New Chairman

Stroma Biosciences, Ltd, a Cambridge based oncology company today announced the appointment of Dr John Beadle as Executive Chairman. Dr Beadle, who previously held the role of CEO at PsiOxus Therapeutics, joins the Stroma Board at a critical time for growth of the...

read more
Seed funding investment

Seed funding investment

We are delighted to have raised seed funding investment from Start Codon. The funding will support the development of our research platform and generation of data for our novel targets. Start Codon link: Startcodon.co

read more
Science Translational medicine Cover

Science Translational medicine Cover

Stroma Biosciences co-founders have been accepted as the cover story in Science Translational Medicine for their work on the tumour microenvironment. The research found that treating the normal cells near to the cancer cells with small molecule inhibitors...

read more